This article is more than 5 years old. Information may no longer be current.
Liventa, Cryoport enter agreement for delivery of cell-based biologic tissue
Click Here to Manage Email Alerts
Liventa Bioscience and Cryoport Inc. announced a major strategic alliance aimed at serving the many points of orthopedic care delivery with Liventa’s cell-based, advanced biologic tissue forms.
According to a press release, the exclusive agreement combines Cryoport’s proprietary, purpose-built cold chain logistics solutions for cell based and advanced biologic tissue forms with Liventa Bioscience’s distribution capability to point-of-use U.S.-based orthopedic care providers. As a result of the alliance, Liventa will now be able to provide Cryoport Express Shippers and Cryoport’s Logistics Management Platform to all advanced biologics suppliers within the orthopedic arena. This logistic system and the small portable cold chain containers will enable Liventa to better serve small or mobile clinics, pharmacies, family practice and orthopedic specialty care providers. Surgical centers and hospitals will also benefit from better logistics and the elimination of issues surrounding dry ice transport and storage, based on the release.
“After careful research, we concluded that Cryoport’s logistics solutions, which include both shipping and information logistics, was by far the most advanced solution available for both our AmnioClear cryopreserved tissue products and other cryopreserved cellular products,” Robin Young, chief executive officer of Liventa, stated. “Cryoport’s system opens up every corner of the orthopedic industry to advanced biologic tissue and cell forms.”